First Patient Enrolled in Ph 1 Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
“The enrollment of the first patient with EVM14 in the United States marks an important achievement in advancing the global clinical development of our in-house mRNA platform.” said Rogers Yongging Luo, Chief Executive Officer of Everest Medicines. “This progress demonstrates Everest’s continued efforts to translate technological innovation into clinical practice and our first move advantage in developing next-generation immuno-oncology therapies, including therapeutic mRNA cancer vaccines. The large patient population faces limited options with existing standard-of-care therapies, highlighting an unmet medical need. As a TAA cancer vaccine, EVM14’s unique mechanism offers the potential to complement current treatments by enhancing the efficacy via combination therapies and helping delay disease recurrence, offering hope for long-term cancer-free survival. With EVM14 receiving IND approval from China’s NMPA, we look forward to this innovative therapy demonstrating promising therapeutic potential in global multicenter clinical trials, bringing more treatment options to patients worldwide and enhance their quality of life.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us